BCM
RANI icon

Bronte Capital Management’s Rani Therapeutics RANI Stock Holding History

Bronte Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,868
Closed -$10.9K – 67
2026
Q1 		$10.9K Hold
14,868
– – ﹤0.01% 53
2025
Q4 		$20.1K Buy
+14,868
New +$22.4K ﹤0.01% 43

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bronte Capital Management's RANI Position: Q2 2026 in Review

Bronte Capital Management sold out of Rani Therapeutics (RANI) in Q2 2026, closing a stake of 14,868 shares — an estimated $10.9K sold.

Bronte Capital Management first reported a position in RANI in Q4 2025 and held it in 2 quarters. The position peaked at $20.1K in Q4 2025. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Bronte Capital Management reported no remaining Rani Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bronte Capital Management sold 14,868 Rani Therapeutics shares in Q2 2026, an estimated $10.9K.
  • Bronte Capital Management first reported a position in Rani Therapeutics in Q4 2025 and held it in 2 quarters.
  • Bronte Capital Management's Rani Therapeutics position peaked at $20.1K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.